Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
CALGARY, Alberta, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed its previously announced private placement of 60,416,667 equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. ("Hepalink") at a price of $1.44 per unit for gross proceeds of $87 million. Each unit was comprised of one common share and 0.082759 of a common share purchase warrant. Each full warrant is exercisable at a price of $1.64 per share for a period of four years from the closing of the offering.
After giving effect to the private placement, the Company has a total of 175,040,756 common shares issued and outstanding. Hepalink holds 75,020,000 common shares and 7,333,333 common share purchase warrants which represents 42.86 percent of the common shares outstanding before giving effect to any outstanding warrants and 45.16 percent of the outstanding common shares assuming the exercise by Hepalink of its warrants.
The net proceeds of the offering will primarily be used to repay the Company's $68.8 million secured loan which matures on December 26, 2017.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please contact:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the use of proceeds from the private placement of equity units, and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Resverlogix Corp via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
GlobeNewswire Test Release16.6.2018 07:00 | Pressemelding
LOS ANGELES, June 15, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539
INVNT/IP: US Responds to Nation-sponsored Crown-jewel Intellectual Property Theft15.6.2018 23:34 | Pressemelding
US Announcement of Large-Scale Tariffs in Response to Chinese Crown-Jewel Intellectual Property Theft Lauded by IP Protection Consortium INVNT/IP SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- The Trump administration today announced 25% tariffs on $50 billion in Chinese goods, representing the first time the United States government has marked sectors in US-China trade for retaliation as a response to theft of crown-jewel intellectual property. In a public statement, President Trump announced that the measures were targeted toward goods that "contain industrially significant technologies." US Trade Representative Robert Lighthizer applauded the move on Fox News, noting, "It's thorough. It's moderate. It's appropriate." In a further explanation of the move, he added, "What I want to do is make sure that we protect our technology here at home, that we stop cybertheft and forced technology transfer, and ultimately, remember: 'China 2025' is a $300 billion subsidy program. The United States h
Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders15.6.2018 22:30 | Pressemelding
BROOKFIELD, NEWS, June 15, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX:BAM.A) (NYSE:BAM) (Euronext:BAMA) today announced that at the company's annual and special meeting of shareholders held earlier today in Toronto, approximately 92% of Class A Limited Voting Shares ("Class A Shares") voted in favour of an advisory vote approving the company's approach to executive compensation. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares ("Class B Shares") were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 620,669,437 99.53 2,921,9
NEP Completes Acquisition of Telerecord15.6.2018 13:53 | Pressemelding
FLORENCE, Italy, June 15, 2018 (GLOBE NEWSWIRE) -- Today NEP Group, a leading outsourced technical production partner supporting premier content producers of live sports and entertainment, announced that it has completed its acquisition of Telerecord, an Italy-based provider of outside broadcast solutions. Telerecord, a local industry leader with strong client relationships, covers popular sporting events in Italy and throughout Southern Europe including football, ice hockey and bobsleigh. The deal further diversifies NEP's business and expands its reach in Europe by adding additional local resources and talent. As part of the deal, all Telerecord staff members will join NEP. Telerecord will be rebranded as NEP and will be part of NEP Italy, which is led by Sergio Cecchini, GM of NEP Italy, who joined NEP in May. Telerecord also brings a fleet of several outside broadcast trucks, sprinter vans and motorcycles to the NEP Worldwide Network to serve clients across Europe. "We couldn't be
Fortuna Reports Results of Annual General Meeting15.6.2018 11:00 | Pressemelding
VANCOUVER, British Columbia, June 15, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) hereby announces the voting results at the Company's annual general meeting held on June 14, 2018. A total of 108,538,241 common shares were represented at the meeting, being 68% of the Company's issued and outstanding shares. Shareholders voted in favour of all matters brought before the meeting including the appointment of auditors, the election of management's nominees as directors, and the ratification and approval of the Company's amended Advance Notice Policy. Detailed results of the votes on the election of directors are as follows: Director Votes For Votes Withheld Jorge Ganoza Durant Simon Ridgway Mario Szotlender David Farrell David Laing Alfredo Sillau Kylie Dickson 74,947,635 (97.4%) 63,448,600 (82.5%) 70,831,225 (92.1%) 74,816,864 (97.3%) 73,597,731 (95.7%) 75,716,342 (98.4%) 76,476,115 (99.4%) 1,930,230 (2.5%) 13,429,266 (17.4%) 6,046,640 (7.9%) 2,061,001 (2.7%) 3
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 201815.6.2018 07:31 | Pressemelding
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden. The preclinical eryaspase data will be presented during Poster Session I by Dr. Karine Aguera, ERYTECH's R&D Project Leader. Poster Session: Preclinical Demonstration of Intracellular Activity of Asparaginase Encapsulated in Red Blood Cells Both in the Absence and in the Presence of Neutralizing Anti-Asparaginase Antibodies Abstract #: PF160 Lead Author: Karine A
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom